MedTrace Logo

Study to Evaluate the Efficacy, Safety, Tolerability and Immunogenicity of 100µg NIC002 Vaccine in Cigarette Smokers Who Are Motivated to Quit Smoking.

NCT00736047 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2017-03-21

No results posted yet for this study

Summary

This study is designed to determine the efficacy of high nicotine-specific antibody titers in smoking cessation.

Conditions

  • Smokers

Interventions

BIOLOGICAL

NIC002

BIOLOGICAL

Placebo

Sponsors & Collaborators

Principal Investigators

  • Novartis · Novartis Investigator Site

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-08-31
Primary Completion
2009-10-31
Completion
2009-10-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00736047 on ClinicalTrials.gov